The Next AI Bottleneck Isn’t Chips. It’s Biology

The AI Biotech Paradox

Moderna’s Phase 3 melanoma data with Merck provides another validation point for AI-assisted personalized cancer vaccines. But investors risk treating this like a software trade, and biology is not software.

AI can generate thousands of biological designs in seconds, but physically synthesizing, testing and validating them can still take months.